BlackRock, Inc. 13D and 13G filings for Y-mAbs Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-26 5:26 pm Purchase |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BlackRock Inc. BLK |
2,917,080 6.700% |
338,304 (+13.12%) |
Filing |
| 2023-02-01 4:54 pm Sale |
2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BlackRock Inc. BLK |
2,578,776 5.900% |
-188,584 (-6.81%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BlackRock Inc. BLK |
2,767,360 6.300% |
348,780 (+14.42%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BlackRock Inc. BLK |
2,418,580 6.000% |
452,462 (+23.01%) |
Filing |